Back to Authors

Sun, Chao

0000-0001-6869-9944

Mayo Clinic

Biogen (United States)

Citations 2

Polyglutamine (CAG) Intermediate Repeat Expansions in ATXN2 is Associated with a More Aggressive Form of ALS Across Multiple Independent Cohorts (2094)
Hurt, Jessica A. , Wuu, Joanne , Ford, Alice F., Elman, Lauren , McCluskey, Leo, Liu, Mei , Chang, Ih , Rademakers, Rosa , Benatar, Michael, Harms, Matthew, Currier, Nicolas , McMillan, Corey T. , Tsai, Ellen A. , Deerlin, Vivianna M. Van , Quinn, Colin , Liu, Mei, Blitterswijk, Marka van , Sun, Chao , Harms, Matthew B.

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.2094 Get It

LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy
Lee, Kelsey , Nguyen, Khanh-Dung H., Liu, Mei , Zafar, Faria , Saetern, Jimmy, Flierl, Adrian , Tetrud, James W., Langston, J. William, Schüle, Birgitt , Sun, Chao , Dickson, Dennis W.

Journal of Parkinson’s Disease | February 20, 2018 | Volume: 8 | Issue: 1 | Pages: 93-100

10.3233/jpd-171237 Get It

Background: Mutations in the leucine rich repeat kinase 2 ( LRRK2) gene are among the most common genetic causes of Lewy body Parkinson’s disease (PD). However, LRRK2 mutations can also lead to a variety of pathological phenotypes other than typical PD, including relatively pure nigrostriatal cell loss without alpha-synuclein-positive Lewy bodies or Lewy neurites, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA). The mechanisms behind this remarkable pleomorphic pathology are currently unclear. Objective: To genetically and pathologically characterize a case with a LRRK2, p.Ile1371Val rare variant and pathologically proven MSA. Methods: From the brain donation program at the Parkinson’s Institute and Clinical Center, we selected 26 brains with family history and a with clinicopathological diagnosis of PD ( n = 20), MSA ( n = 4), or PSP ( n = 2). We performed neuropathological evaluation, including alpha-synuclein and tau immunohistochemistry and sequenced 188 genes that have been reported as causative for or associated with neurodegenerative diseases. Results: We identified a known LRRK2, p.Ile1371Val genetic variant in a case with clinically diagnosed and pathologically proven MSA. Neuropathology revealed that the olivopontocerebellar system was more affected than the striatonigral system. Conclusions: Our data suggest that genetic variants in the LRRK2 gene can present clinically and neuropathologically as MSA. One other LRRK2 genetic variant ( LRRK2, p.Ile2020Thr) has been reported with a neuropathological diagnosis of MSA. Interestingly, the LRRK2 variant ( LRRK2, p.Ile1371Val) identified here has been reported previously in a postmortem case with Lewy body PD. Future studies are critical to discover the mechanisms leading to different neurodegenerative trajectories both in neuronal and glial cell populations.